Recent Articles from GlobeNewswire

AI & Technology Virtual Investor Conference Agenda Announced for April 23rd
Company executives will discuss their business strategies, provide updates on recent developments, and answer questions live at VirtualInvestorConferences.com
By Virtual Investor Conferences · Via GlobeNewswire · April 20, 2026
01 Quantum to Present at the AI & Tech Virtual Investor Conference April 23rd
TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- 01 Quantum Inc. (“01 Quantum” or the “Company”) (TSX-V: ONE; OTCQB: OONEF), one of the first-to-market, enterprise level cybersecurity providers for the quantum computing era, announces that CEO Andrew Cheung will present live at the AI & Tech Virtual Investor Conference hosted by VirtualInvestorConferences.com, on April 23rd, 2026.
By Virtual Investor Conferences · Via GlobeNewswire · April 20, 2026
From Ukraine to the Middle East, GPS Disruption Drives Demand for Next-Generation Defense Technology
AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: For decades, GPS has operated as the invisible infrastructure underpinning modern warfare, enabling everything from precision-guided munitions to autonomous drone navigation. That assumption of reliability is now disappearing in real time. Across active conflict zones, satellite navigation signals are being jammed, spoofed and degraded at scale, turning one of the most trusted systems in defense into one of its most vulnerable. The consequences are immediate and measurable: Drones lose positioning, missions fail mid-operation and entire systems become ineffective in contested environments. As electronic warfare capabilities advance, GPS is increasingly becoming the first system adversaries attempt to disable, forcing a rapid reassessment of how modern platforms operate without it. In response, defense organizations worldwide are accelerating the search for alternatives that can function independently of satellite signals.
By AINewsWire · Via GlobeNewswire · April 20, 2026
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being reinforced by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), are keenly aware of this evolution and are leveraging their expertise as pioneers in this space. Through its diversified pipeline and strategic holdings, including a 45% ownership stake in GMP Bio, which was recently measured at more than $1 billion enterprise value, the company exemplifies how advancing science can directly influence financial positioning. As the biotech sector increasingly aligns valuation with progress rather than revenue alone, Oncotelic provides a case study in how innovation is becoming a recognized asset class. Oncotelic joins an elite group of other key companies focused on advanced biotech platforms that target disease at the genetic or molecular level, including Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Denali Therapeutics Inc. (NASDAQ: DNLI)
By BioMedWire · Via GlobeNewswire · April 20, 2026
1847 Holdings Subsidiary Wolo Receives Approval of Amazon Brand Registry, Expanding E-Commerce Presence
Wolo targeting approximately $5 million in revenue and $1 million in EBITDA by fiscal year 2027
By 1847 Holdings LLC · Via GlobeNewswire · April 20, 2026
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
Translational study in metastatic triple-negative breast cancer (mTNBC) shows leronlimab-mediated CCR5 inhibition induces PD-L1 expression, modulates immune checkpoint signaling, and is associated with long-term survival in heavily pretreated patients
By CytoDyn Inc. · Via GlobeNewswire · April 20, 2026
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego, Calif.
By Allogene Therapeutics, Inc. · Via GlobeNewswire · April 20, 2026
Anthony, Linder & Cacomanolis Releases Strategic Analysis on PayPay IPO; Transaction Solidifies "Japan Corridor" to U.S. Capital Markets
WEST PALM BEACH, Fla. and TOKYO, April 20, 2026 (GLOBE NEWSWIRE) -- Anthony, Linder & Cacomanolis, PLLC (“ALC”), a premier international capital markets and U.S. securities law firm, provides a strategic analysis of the March 12, 2026, Nasdaq Global Select Market debut of PayPay Corporation (Nasdaq: PAYP). The firm identifies the transaction as a seminal event for the Japanese "super-app" ecosystem and a repeatable structural blueprint for navigating the U.S. markets through the strategic alignment of Japanese domestic technology with U.S. institutional valuation expectations.
SAIC Awarded New $75.2M PRISM Task Order to Advance the Naval Air Systems Command’s Mission-Critical Aviation Systems
Contract modernizes and sustains the technology and infrastructure of Aircraft Armament Equipment (AAE), Support Equipment (SE), and Aerial Refueling System (ARS) integration for the MQ-25, building on SAIC’s 20-year partnership with the U.S. Navy
By SAIC, Inc. · Via GlobeNewswire · April 20, 2026
GDA Luma Leads Pat McGrath Labs Into Its Next Chapter of Growth
Strengthened Operations, Reinforced Retail Partnerships, and New Capital Position the Iconic Beauty House for Long-Term Success
Rachio Offers 20% Off Smart Sprinkler Controllers Nationwide April 19–26
A week-long Earth Day promotion gives homeowners a timely opportunity to upgrade before summer watering season
By Rachio · Via GlobeNewswire · April 20, 2026
Camp Southern Ground Announces CEO Transition: Founder Zac Brown Welcomes Michael “Mike” Caimona; Longtime CEO Mike Dobbs to Retire
Fayetteville, Georgia, April 20, 2026 (GLOBE NEWSWIRE) -- Camp Southern Ground founder Zac Brown and the organization’s Board of Directors today announced a leadership transition, naming Michael (“Mike”) Caimona as the nonprofit’s next Chief Executive Officer. Caimona is expected to begin in May 2026, succeeding longtime CEO Mike Dobbs, retiring after a decade of leadership.
By Camp Southern Ground · Via GlobeNewswire · April 20, 2026
Turbo Energy and Hithium Partner to Integrate AI-Driven Energy Optimization Software Into Battery Storage Systems Across Europe and Latin America
Partnership enables the integration of Turbo Energy’s AI-driven software into battery storage systems, supporting expansion of its high-margin international C&I pipeline
By Turbo Energy S.A. · Via GlobeNewswire · April 20, 2026
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
Company Advances Next-generation Patented MDMA Toward Patient Dosing in 2026
By PharmAla Biotech · Via GlobeNewswire · April 20, 2026
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today welcomed the White House Executive Order aimed at accelerating research, regulatory pathways, and patient access to psychedelic treatments.
By Helus Pharma · Via GlobeNewswire · April 20, 2026
Nanox Signs Commercial Agreement with Howard Technology Solutions to Deploy 300 Nanox.ARC Systems Across U.S. Over Three Years
Howard’s nationwide reach across healthcare and public sector markets expands Nanox’s U.S. channel partner network to additional customer segments
By NANO-X IMAGING LTD · Via GlobeNewswire · April 20, 2026
YY Group Reports Unaudited Second Half and Full Year 2025 Earnings Results Highlighting Accelerating Revenue Growth, Expanding Margins and Positioning for Profitability in 2026
Full year revenue grew 39.3% year over year to US$57.2 million, with second half revenue of US$31.5 million
By YY Group · Via GlobeNewswire · April 20, 2026
dLocal Limited Announces Dismissal of New York State Securities Class Action
MONTEVIDEO, Uruguay, April 20, 2026 (GLOBE NEWSWIRE) -- DLocal Limited (NASDAQ: DLO, “dLocal” or the “Company”), a leading cross-border financial infrastructure platform connecting global merchants to emerging markets, today announced that the Supreme Court of the State of New York, Appellate Division, First Department, has unanimously affirmed the dismissal of the putative class action lawsuit captioned In the Matter of DLocal Securities Litigation, Index No. 151778/23 (the “New York State Action”). The Supreme Court, New York County had previously granted the defendants’ motion to dismiss the complaint in its entirety, and the Appellate Division has now unanimously upheld that decision.
By DLocal Limited · Via GlobeNewswire · April 20, 2026
Safe Pro Reports on Share Repurchase Program, Reinforcing Commitment to Shareholder Value and Capital Return
Company Has Repurchased 400,000 Common Shares in Open Market Transactions
By Safe Pro Group Inc. · Via GlobeNewswire · April 20, 2026
Fiserv to Release First Quarter Earnings Results on May 5, 2026 and Confirms Details for May 14, 2026 Investor Day
MILWAUKEE, April 20, 2026 (GLOBE NEWSWIRE) -- Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology solutions, will announce its first quarter financial results before the market opens on Tuesday, May 5, 2026. The company will discuss its results in a live webcast at 7 a.m. CT (8 a.m. ET) on May 5, 2026. The webcast, along with supplemental financial information, can be accessed on the investor relations section of the Fiserv website at investors.fiserv.com. A replay will be available approximately one hour after the conclusion of the live webcast.
By Fiserv, Inc. · Via GlobeNewswire · April 20, 2026
Nanox Announces Fourth Quarter of 2025 Financial Results and Provides Business Updates
Advanced commercialization in the US, signing multiple new customer and distribution agreements for Nanox.ARC and accelerated activities around Nanox.AI
By Nano-X Imaging Ltd · Via GlobeNewswire · April 20, 2026
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California on April 19, 2026. The Company demonstrated new data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment (“TME”). The poster is available here.
By Calidi Biotherapeutics, Inc · Via GlobeNewswire · April 20, 2026
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2026 financial results will be released on Monday, April 27, 2026, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
By Fulcrum Therapeutics, Inc. · Via GlobeNewswire · April 20, 2026
Cole West Closes on 38 Homesites in Northern Utah for New Community
Single-family homes in the Lone Tree community coming to Davis County
By Cole West · Via GlobeNewswire · April 20, 2026
Axe Compute Unveils Compute Reserve Dashboard, Giving Investors a Unified View of Its NASDAQ Stock and Operational Strategic Compute Reserve
Purpose-built for the neocloud era: a unified view of Axe Compute's NASDAQ equity and its Strategic Compute Reserve (SCR), the operational reserve that funds enterprise access to 435,000+ GPUs across 200+ global locations
By Axe Compute Inc · Via GlobeNewswire · April 20, 2026
Abacus Global Management to Participate in the 2026 Milken Institute Global Conference
ORLANDO, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. ("Abacus" or the "Company") (NYSE: ABX), a leader in the alternative asset management industry, today announced that it will participate in the 2026 Milken Institute Global Conference, taking place May 3–6, 2026 at The Beverly Hilton and Waldorf Astoria Beverly Hills in Beverly Hills, CA. The announcement marks the Company's first appearance at the annual gathering, which convenes thousands of leaders from across finance, business, government, health and philanthropy.
By Abacus Global Management · Via GlobeNewswire · April 20, 2026
2027 Kia Telluride Adds Hybrid Option Rated at Up to 35 MPG
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- (Feature Impact) Three-row SUVs continue to evolve as drivers look for vehicles that balance everyday practicality with comfort, technology and capability. Automakers are responding with models designed to support family life, long road trips and outdoor travel.
By Feature Impact · Via GlobeNewswire · April 20, 2026
The Double D Foundation Announces Major Gift From Patriot Mobile
Black Creek, GA, April 20, 2026 (GLOBE NEWSWIRE) -- Today, The Double D Foundation announced a significant financial commitment from Patriot Mobile, America’s only Christian conservative wireless provider. The announcement was made at the NRA Annual Meetings & Exhibits in Houston, Texas, underscoring the national significance of this investment and Patriot Mobile’s continued leadership in defending constitutional freedoms.
By Patriot Mobile · Via GlobeNewswire · April 20, 2026
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
BRIDGEWATER, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the 2026 American Academy of Neurology (AAN).
By Amneal Pharmaceuticals LLC · Via GlobeNewswire · April 20, 2026
ZJK Industrial Co., Ltd. Advances Localization Strategy in Vietnam to Strengthen Global Production Network
SHENZHEN, China, April 20, 2026 (GLOBE NEWSWIRE) -- ZJK Industrial Co., Ltd. (NASDAQ: ZJK) (“ZJK Industrial”, “ZJK” or the “Company”), a high-tech precision parts and hardware manufacturer serving artificial intelligence (AI) infrastructure, consumer electronics, electric vehicles, aerospace, and other smart technologies, today announced that it is advancing a localized operational model for its Vietnamese subsidiary as part of its ongoing global operations planning to support a more balanced and sustainable global production network.
By ZJK Industrial Co., Ltd. · Via GlobeNewswire · April 20, 2026
Aptean introduces AI platform and AI agents for Business Central On-Premises Customers
Offering Partners a New Recurring-Revenue Opportunity — Exclusive Preview at Directions North America
By Aptean Inc. · Via GlobeNewswire · April 20, 2026
MainStreet Bancshares, Inc. Announces First Quarter 2026 Results
Net Interest Margin Expands on Disciplined Funding Strategy
By MainStreet Bancshares, Inc. · Via GlobeNewswire · April 20, 2026
Atsena Therapeutics Receives Data Monitoring Committee Recommendation to Proceed with Pivotal Part C Cohort of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
Patient screening to begin this month
By Atsena Therapeutics · Via GlobeNewswire · April 20, 2026
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer
This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.
By Helus Pharma · Via GlobeNewswire · April 20, 2026
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W. Ettenberg, a seasoned leader with more than 25 years of legal experience in the biopharmaceutical industry, as Chief Legal Officer (CLO). She will oversee Ardelyx’s legal, compliance, regulatory, and government affairs operations. Ms. Ettenberg succeeds Elizabeth Grammer, who has chosen to retire after an extraordinary 16-year career at the company.
By Ardelyx, Inc. · Via GlobeNewswire · April 20, 2026
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV108, an Allosteric SARM1 inhibitor
Second candidate from Tenvie’s product engine to enter clinical development
By Tenvie Therapeutics, Inc. · Via GlobeNewswire · April 20, 2026
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
MHRA submission follows EMA validation of the VIZZ MAA in March 2026
By LENZ Therapeutics, Inc. · Via GlobeNewswire · April 20, 2026
Mountain Warehouse Launches Composable Ecommerce Store with BigCommerce to Accelerate Innovation and Global Growth
Outdoor retailer replaces legacy system with modern, headless architecture to improve scalability, flexibility and customer experience
By Commerce.com, Inc. · Via GlobeNewswire · April 20, 2026
AskBio's Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease
Berlin, Germany, and Durham, N.C., USA, April 20, 2026 (GLOBE NEWSWIRE) -- Not intended for UK Media
By AskBio Inc. (AskBio) · Via GlobeNewswire · April 20, 2026
Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK’s Knowledge Quarter
Ingelheim, Germany, and London, UK – Boehringer Ingelheim today announced the expansion of its global Computational Innovation footprint with the launch of a new center for AI and machine learning in King’s Cross, London, UK, part of the Knowledge Quarter ecosystem. As the company continues to innovate and expand its AI capabilities in pharmaceutical R&D, this significant investment recognizes the UK’s commitment to AI and the life sciences sector.
By Boehringer Ingelheim Limited · Via GlobeNewswire · April 20, 2026
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial 
By Kyverna Therapeutics, Inc. · Via GlobeNewswire · April 20, 2026
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, April 30, 2026, to report its first quarter 2026 financial results and provide a business update.
By Phathom Pharmaceuticals · Via GlobeNewswire · April 20, 2026
RedCloud to Enter Live Deployment Phase as Combined Turkey and Saudi Joint Ventures Represent Up to $80 Million Revenue
Joint ventures underpin up to $80 million in contracted value across key global trade corridors, marking a transition to early-stage deployment with one of Turkey’s leading distribution networks
By RedCloud Holdings plc · Via GlobeNewswire · April 20, 2026
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company’s strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company’s development strategy.
By NewcelX Ltd. · Via GlobeNewswire · April 20, 2026
Nexera: KeepZone AI Enters into White Label Agreement to Develop its AI-Based Voice Communication Decision Support System
Tel Aviv, Israel, April 20, 2026 (GLOBE NEWSWIRE) -- Nexera Technologies Ltd (“Nexera” or the “Company”) (Nasdaq: NEXR, NEXRW) (formerly known as Jeffs’ Brands Ltd), a data-driven company operating on the Amazon Marketplace expanding into the global homeland security sector through advanced artificial intelligence (“AI”) – driven solutions, today announced that its wholly-owned subsidiary, KeepZone AI Inc. (“KeepZone”), has entered into a strategic white label agreement with a third-party technology provider for the development of KeepZone’s AI-powered voice communication decision support system (the “Agreement”).
By Nexera Technologies Ltd · Via GlobeNewswire · April 20, 2026
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma (“TJ Bio”) today announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio’s exclusive rights to felzartamab in the Greater China Region. With this agreement, Biogen now owns exclusive worldwide rights to felzartamab, which is currently being evaluated in global Phase 3 clinical studies across multiple immune-mediated diseases.
By Biogen Inc. · Via GlobeNewswire · April 20, 2026
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children’s Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ET
By Palvella Therapeutics Inc. · Via GlobeNewswire · April 20, 2026
Cronos Group Inc. to Hold 2026 First Quarter Earnings Conference Call on May 11, 2026
TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 first quarter earnings conference call on Monday, May 11, 2026 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.
By Cronos Group Inc. · Via GlobeNewswire · April 20, 2026
Weight Watchers Appoints Proven Healthcare Executive Heather Thiltgen to Board of Directors
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced that it has appointed Heather Thiltgen to the Company’s Board of Directors, effective April 20, 2026. Ms. Thiltgen currently serves as the President of Presbyterian Health Plan and previously served as President & CEO of WellSense Health Plan.
By WW International Inc. · Via GlobeNewswire · April 20, 2026
Swvl Announces FY 2025 Results; Revenue Up 41% to $24.2 million; Net Income $1.3 million; NDR of 128%; GCC Revenue Up 122%
Net income of $1.3M in FY 2025 versus net loss of $10.3M in FY 2024
By Swvl Holdings Corp · Via GlobeNewswire · April 20, 2026
New Found Gold Announces $205M Finance Package
$100M bought deal financing with lead orders from EdgePoint and cornerstone investor Eric Sprott$105M Senior Secured Credit Facility with EdgePoint
By New Found Gold Corp. · Via GlobeNewswire · April 20, 2026
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, recently announced that CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD) has met the primary endpoint in its FDA-approved Phase I/IIa clinical trial.
By Clearmind Medicine Inc. · Via GlobeNewswire · April 20, 2026
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, is a featured speaker at the POLITICO Health Care Summit on Tuesday, April 21. During the session, Mr. Elia will frame the evolving landscape of viral disease prevention, including the role of monoclonal antibodies in keeping Americans healthy moving forward.
By Invivyd · Via GlobeNewswire · April 20, 2026
Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer
Proven healthcare growth leader to drive disciplined, profitable expansion and scale across Lumexa Imaging’s platform
By Lumexa Imaging, Inc. · Via GlobeNewswire · April 20, 2026
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels 
By Passage Bio · Via GlobeNewswire · April 20, 2026
SPARC AI Signs Second Ukrainian Drone Manufacturer, Expanding Distribution Footprint for GPS-Denied Software Platform
VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- SPARC AI Inc. (the “Company”) (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) is pleased to announce it has signed a second Ukrainian drone manufacturer to its Overwatch platform, marking continued commercial momentum for the Company's GPS-denied navigation and precision targeting software.
By SPARC AI INC · Via GlobeNewswire · April 20, 2026
TransAlta Appoints Mike Politeski as Chief Financial Officer and Grant Arnold as Chief Commercial Officer
CALGARY, Alberta, April 20, 2026 (GLOBE NEWSWIRE) -- TransAlta Corporation (TransAlta or the Company) (TSX: TA) (NYSE: TAC) is pleased to announce the appointment of Mike Politeski as Executive Vice President, Finance and Chief Financial Officer (EVP and CFO) and Grant Arnold as Executive Vice President, Growth and Chief Commercial Officer (EVP and CCO), effective May 1, 2026 and May 6, 2026, respectively. The appointments correspond with the transition of current EVP and CFO, Joel Hunter, to the role of President and Chief Executive Officer (CEO) effective April 30, 2026, following the retirement of current President and CEO, John Kousinioris.
By TransAlta Corporation · Via GlobeNewswire · April 20, 2026
Soleo Health Expands Rare Disease Capabilities With Launch of SoleoRare™, A Specialty Pharmacy Focused on Complex Patient Needs
New brand reflects years of expertise and a deepened commitment to the rare disease community
By Soleo Health Holdings, Inc. · Via GlobeNewswire · April 20, 2026
Aikido Security Launches Endpoint Protection for Developer Devices as Software Supply Chain Attacks Hit Unprecedented Scale
GHENT, Belgium, April 20, 2026 (GLOBE NEWSWIRE) -- Aikido Security today launched Aikido Endpoint, a lightweight security agent that protects developer devices against software supply chain attacks by inspecting and blocking risky packages, IDE extensions, browser plugins, and AI tools before they're ever installed.
By Aikido Security · Via GlobeNewswire · April 20, 2026
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP) welcomes the newly-signed Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS, signed by President Trump on April 18, 2026. In the Order, the President notes that, “It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America.”
By NRx Pharmaceuticals, Inc. · Via GlobeNewswire · April 20, 2026
Altus Group Announces Exemptive Relief from the Ontario Securities Commission in connection with its Substantial Issuer Bid
TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group” or the “Company”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, announced today that, in connection with its ongoing substantial issuer bid (the “SIB”) to purchase for cancellation up to C$200,000,000 in value of its common shares (the “Shares”), the Ontario Securities Commission (the “OSC”), as Altus Group’s principal regulator, has granted an exemptive relief order exempting Altus Group from complying with certain extension take up, proportionate take up and related disclosure requirements.
By Altus Group Limited · Via GlobeNewswire · April 20, 2026
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers 
By Monte Rosa Therapeutics, Inc. · Via GlobeNewswire · April 20, 2026
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet’s prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effective April 20, 2026.
By Sagimet Biosciences Inc. · Via GlobeNewswire · April 20, 2026
Bodor Laser Ranked No. 1 in Global Sales Volume for Seven Consecutive Years, Demonstrating Brand Strength Through Sustained Leadership
SHENZHEN, China, April 20, 2026 (GLOBE NEWSWIRE) -- Bodor Laser has ranked No. 1 globally in sales of laser cutting machines (1,000W and above) for the seventh consecutive year, according to data released by Qianzhan Industry Research Institute in March 2026. In 2025, the company again exceeded 10,000 units in annual sales, remaining the only manufacturer to achieve this milestone for seven consecutive years.
By Bodor Laser Inc. · Via GlobeNewswire · April 20, 2026
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), presented data evaluating safety margins of administration of deucrictibant immediate-release (IR) capsule(s) in combination with deucrictibant extended-release (XR) tablet at the Consortium of Independent Immunology Clinics (CIIC) Spring 2026 Conference, which took place from April 17-19, 2026, in Arlington, TX.
By Pharvaris N.V. · Via GlobeNewswire · April 20, 2026
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies
By Silo Pharma, Inc. · Via GlobeNewswire · April 20, 2026
Parsons Demand Response Technology to Optimize and Enable Los Angeles Department of Water & Power’s Operations and Strategic Plan
CHANTILLY, Va., April 20, 2026 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that the company has been selected by the Los Angeles Department of Water & Power (LADWP) to provide demand response technology, integration, and services to help manage and optimize the operation of distributed energy sources within the electrical grid.
By Parsons Services Company · Via GlobeNewswire · April 20, 2026
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the pricing of its underwritten offering of 18,018,014 shares of its voting common stock (the “Common Stock”) at a price of $4.44 per share, and, in lieu of Common Stock to investors who so chose, pre-funded warrants to purchase up to 2,252,252 shares of its Common Stock at a price of $4.4399 per pre-funded warrant, which represents the per share offering price for the Common Stock less the $0.0001 per share exercise price for each such pre-funded warrant. Before deducting the underwriting discounts and commissions and estimated offering expenses, the total gross proceeds to Prelude are approximately $90.0 million. The offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.
Solera Introduces AI Engine, a Cloud-Native Intelligence Layer Powering Faster Innovation Across the Automotive Ecosystem
Purpose-built AI infrastructure connects proprietary data, orchestrates workflows, and compresses development timelines significantly
By Solera Global Corp. · Via GlobeNewswire · April 20, 2026
CoatingSolution4U Wins Bronze at the 2026 Edison Awards in Materials Science
Korean Deep-Tech Startup Earns Global Recognition for Battery Manufacturing AI
By CoatingSolution4U Co., Ltd · Via GlobeNewswire · April 20, 2026
Equinor ASA: Notice of annual general meeting 12 May 2026
The annual general meeting of Equinor ASA (OSE: EQNR, NYSE: EQNR) will be held Tuesday 12 May 2026 at 15:00 CEST.
By Equinor ASA · Via GlobeNewswire · April 20, 2026
Howard Hughes Holdings Appoints Former Arch Capital CEO Marc Grandisson to Company’s Board of Directors
Grandisson to Purchase 1,131,273 Five-Year Warrants with $100 Strike Price
By Howard Hughes Holdings Inc. · Via GlobeNewswire · April 20, 2026
OwlTing Group (NASDAQ: OWLS) Announces 12-Month Lock-Up Extension Supported by SBI and Legacy Shareholders Representing More Than 99% of Subject Shares
Extension aims to reflect long-term alignment among core shareholders and is expected to mitigate potential near-term share supply dynamics
By OwlTing Group · Via GlobeNewswire · April 20, 2026
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer 
Vitaquest Highlights Quality Systems Supporting Its Responsibility to Customers and Consumers
Vitaquest outlines quality, packaging, and compliance systems supporting product quality and performance across dietary supplement manufacturing operations
By Vitaquest International LLC · Via GlobeNewswire · April 20, 2026